Printer Friendly Version 

2014 Press Releases

Keyword Search
 
2014 | 2013 | 2012 | 2011
DateTitle 
04/01/14Isis Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference
CARLSBAD, Calif., April 1, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 13th Annual Needham Healthcare Conference on Tuesday, April 8 , 2014 at 12:50 p.m. ET in New York, NY. A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis website within ... 
Printer Friendly Version
03/31/14Isis Reports Final Phase 2 Data On ISIS-APOCIII Rx In Patients With High Triglycerides Taking Fibrates
- Reductions of up to 64 percent in triglycerides achieved - Reductions in atherogenic particles and increases in HDL particles observed - Data presented today at the American College of Cardiology CARLSBAD, Calif., March 31, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the final results from its Phase 2 study of ISIS-APOCIIIRx in patients with high to severely high triglycerides on stable doses of fibrates.  In this study, patients treated with ISIS-APOCIIIR... 
Printer Friendly Version
03/24/14Isis Announces Antisense Targeting Of HBV Produces Dose-Dependent Reductions In Hepatitis B Virus In An Animal Model Of HBV
Data to be presented in April at the European Association for the Study of the Liver Meeting Isis' antisense drug targeting HBV, ISIS-HBVRx, in an ongoing Phase 1 study planned to complete this year CARLSBAD, Calif., March 24, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that treatment with an antisense compound targeting hepatitis B virus (HBV) produced dose-dependent reductions in all measured liver and serum viral markers of HBV infection in animal models of ... 
Printer Friendly Version
03/19/14Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-ANGPTL3 Rx to Treat Hyperlipidemia
CARLSBAD, Calif., March 19, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 clinical study for ISIS-ANGPTL3Rx, an antisense drug targeting angiopoietin-like 3 protein (ANGPTL3), an independent risk factor for cardiovascular disease. ISIS-ANGPTL3Rx is designed to act as a broad dyslipidemia agent.  By reducing ANGPTL3, ISIS-ANGPTL3Rx has the potential to reduce LDL-cholesterol and triglycerides, and to increase insulin sensitivity.  I... 
Printer Friendly Version
03/06/14Isis Pharmaceuticals to Present at the Barclays Global Healthcare Conference
CARLSBAD, Calif., March 6, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Barclays Global Healthcare Conference on Thursday, March 13, 2014 at 9:00 a.m. ET in Miami, FL. A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis website within 48 hour... 
Printer Friendly Version
03/03/14ISIS Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx
CARLSBAD, Calif., March 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of an open-label extension study of ISIS-TTRRx, which is being offered to those patients with familial amyloid polyneuropathy (FAP) who have completed dosing in the Phase 2/3 study of ISIS-TTRRx.  ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyr... 
Printer Friendly Version
02/28/14Isis Reports Financial Results And Highlights For 2013
- Outperforms 2013 Projections for Pro Forma Net Operating Loss and Year-end Cash - Conference Call Webcast Friday, February 28, 11:30 a.m. ET at www.isispharm.com CARLSBAD, Calif., Feb. 28, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2013 financial results and reviewed the highlights of the year.  Isis ended the year in a strong financial position and outperformed both its pro forma net operating loss (NOL) guidance and its cash guidance for the year... 
Printer Friendly Version
02/25/14Isis Pharmaceuticals to Present at the Cowen 34th Annual Health Care Conference
CARLSBAD, Calif., Feb. 25, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Cowen and Company 34th Annual Health Care Conference on Tuesday, March 4, 2014 at 8:40 a.m. ET in Boston, MA. A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis website ... 
Printer Friendly Version
02/21/14Isis Pharmaceuticals Reports Interim Results from ISIS-SMN Rx Phase 2 Study in Infants with Spinal Muscular Atrophy
On track to initiate Phase 3 study in infants with SMA in the middle of this year Conference Call Scheduled for Monday, February 24, 2014 at 8:30 am Eastern Time CARLSBAD, Calif., Feb. 21, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on its ongoing open label, multiple dose Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy (SMA).  To date, all four infants in the 6 mg cohort have been in the study for over six months and are now ... 
Printer Friendly Version
02/21/14Isis Pharmaceuticals Reports Interim Results from ISIS-SMN Rx Multiple Dose Study in Children with Spinal Muscular Atrophy
Average increase of 3.7 points observed in muscle function score in SMA children treated with 9 mg of ISIS-SMN Rx ISIS-SMN Rx increases SMN protein in children with SMA On track to initiate Phase 3 study in children with SMA later this year Conference Call Scheduled for February 24, 2014 at 8:30 am Eastern Time CARLSBAD, Calif., Feb. 21, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced top-line results from an ongoing open-label, multiple-dose study of I... 
Printer Friendly Version
02/20/14Webcast Alert: Isis Pharmaceuticals' 2013 Financial Results and Highlights Conference Call
CARLSBAD, Calif., Feb. 20, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' 2013 Financial Results and Highlights Conference Call When: Friday, February 28 at 11:30 a.m. ET / 8:30 a.m. PT Where: www.isispharm.com How: Live on the Internet.  Simply log onto our website listed above. ... 
Printer Friendly Version
02/19/14Isis Pharmaceuticals to Present at the 2014 RBC Capital Markets Global Healthcare Conference
CARLSBAD, Calif., Feb. 19, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2014 RBC Capital Markets Global Healthcare Conference on Wednesday, February 26, 2014 at 2:05 p.m. ET in New York, NY. (Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO) A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company... 
Printer Friendly Version
02/14/14Isis Announces Positive Opinion on European Orphan Drug Designation for ISIS-TTR Rx
CARLSBAD, Calif., Feb. 14, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending ISIS-TTRRx for designation as an orphan medicinal product for the treatment of ATTR-Amyloidosis to the European Commission (EC). The opinion will be subject to review by the EC, which ultimately grants the decision on orphan drug designation.  ATTR-Amyloidosis, or TTR amyloidosis, is a severe ... 
Printer Friendly Version
02/13/14Isis Pharmaceuticals Advances ISIS-SMN Rx in Infants and Children with Spinal Muscular Atrophy
--Isis will receive $9.3 million in milestone payments -- CARLSBAD, Calif., Feb. 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the first child in the 12 mg group was dosed in the ongoing Phase 2 study evaluating ISIS-SMNRx in children with spinal muscular atrophy (SMA).  Isis also announced today that the first child was dosed in an open–label extension study, which is being offered to those children with SMA who have completed dosing in Isis' previou... 
Printer Friendly Version
02/06/14Isis Pharmaceuticals to Present at the Leerink Global Healthcare Conference
CARLSBAD, Calif., Feb. 6, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2014 Leerink Global Healthcare Conference on Thursday, February 13, 2014 at 1:50 p.m. ET in New York, NY. (Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO) A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's website, ww... 
Printer Friendly Version
02/03/14Joseph Loscalzo, M.D., Ph.D., Joins Isis Pharmaceuticals' Board of Directors
CARLSBAD, Calif., Feb. 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that Joseph Loscalzo, M.D., Ph.D., has joined the company's Board of Directors.  Dr. Loscalzo is head of the department of medicine and physician-in-chief at Brigham & Women's Hospital, Harvard Medical School.  Dr. Loscalzo is recognized as a leading cardiologist focused on identifying the role of endothelial cells and platelets in atherosclerosis and thrombosis. (Logo: http://photos.p... 
Printer Friendly Version
01/13/14Isis Pharmaceuticals to Receive $7.5 Million From Alnylam
CARLSBAD, Calif., Jan. 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will receive $7.5 million from Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from the recently announced alliance between Genzyme and Alnylam.  In addition, Isis has the potential to receive royalties on products and a portion of future milestone payments.  This transaction underscores the value of Isis' innovation and the leadership role Isis has played in the field of nucleic acid b... 
Printer Friendly Version
01/13/14Isis Announces Positive Decision on European Orphan Drug Designation for ISIS-APOCIII Rx
CARLSBAD, Calif., Jan. 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for Orphan Drug Designation for ISIS-APOCIIIRx for the treatment of patients with familial chylomicronemia syndrome (FCS).  FCS is a rare orphan disease characterized by extremely high triglyceride levels that affects an estimated 3,000 to 5,000 patients worldwide. ISIS-APOCIIIRx is a wholly owned drug that... 
Printer Friendly Version
01/06/14Isis Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
CARLSBAD, Calif., Jan. 6, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 32nd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2014 at 4:30 p.m. PT in San Francisco, CA. (Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO) A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's websi... 
Printer Friendly Version

Online Investor Kit

Quickly download files right from our Investor Relations Web site.

Learn More

Financial Tearsheet

Download a brief overview of Isis.

Learn More

News Feeds

Get the latest.

Subscribe

Receive Isis alerts in your email.

Sign Up